This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal

A Five-Year Review

Charles B. Wilson, MD; Philip Gutin, MD; Edwin B. Boldrey, MD; David Crafts, MD; Victor A. Levin, MD; K. Jean Enot, MD

Arch Neurol. 1976;33(11):739-744.

Abstract
• Identification of effective single chemotherapeutic agents for brain tumors must precede the rational use of multiple drug combinations. In phase 2 trials beginning in 1968, 158 patients with intrinsic brain tumors (mostly recurrent malignant astrocytomas) were considered evaluable.

The larger trials with more effective drugs produced these results: carmustine (BCNU) response rate, 47%, with median duration of nine months; lomustine (CCNU), 44%, with median duration of six months; procarbazine hydrochloride, 52%, with median duration six months; carmustine and vincristine sulfate combined, 44%, with median duration of only four months; and BIC (5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide), 38%, with median duration of five months. Administration of glucocorticoids was not found to bias the frequency of response.

Forty-seven patients, 26 of whom had responded to the initial drug, received a second drug. Among 26 patients who were evaluable, only four responded to the second drug.

Author Affiliations
From the departments of neurological surgery (Drs Wilson, Gutin, Boldrey, Levin, Enot, and Crafts), neurology (Dr Levin), and pharmaceutical chemistry (Dr Levin), University of California School of Medicine, San Francisco.

Footnotes
Accepted for publication March 10, 1976.

Reprint requests to Neurosurgical Editorial Office, 350 Parnassus Heights, Suite 807, University of California, San Francisco, CA 94143 (Dr Wilson).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Effect of Enzyme-Inducing Antiseizure Drugs on the Pharmacokinetics and Tolerability of Procarbazine Hydrochloride
Grossman et al.
Clin. Cancer Res. 2006;12:5174-5181.
ABSTRACT | FULL TEXT  

In vitro Drug Response and Molecular Markers Associated with Drug Resistance in Malignant Gliomas
Fruehauf et al.
Clin. Cancer Res. 2006;12:4523-4532.
ABSTRACT | FULL TEXT  

Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide
Brada et al.
Ann Oncol 2005;16:942-949.
ABSTRACT | FULL TEXT  

Intracranial Tumors--Panel 2
Chou et al.
Arch Neurol 1979;36:739-749.
ABSTRACT